Phase II Trial of Increased Dose Rituximab Plus Maintenance Rituximab for Initial Systemic Treatment of Indolent B-Cell Lymphomas.
Phase of Trial: Phase II
Latest Information Update: 11 Jun 2017
At a glance
- Drugs Rituximab (Primary)
- Indications B cell lymphoma; Follicular lymphoma; Marginal-zone-B-cell-lymphoma
- Focus Therapeutic Use
- 29 Mar 2017 Status changed from active, no longer recruiting to completed.
- 17 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 17 Dec 2016 Planned primary completion date changed from 1 Dec 2014 to 1 Jan 2017.